Genomic tests, such as Oncotype DX and MammaPrint, enable many patients with early-stage, hormone-receptor-positive (HR+), HER2-negative breast cancer to safely avoid chemotherapy. According to the National Comprehensive Cancer Network (NCCN), these assays analyze the expression of specific genes in tumor tissue to predict the likelihood of recurrence and the potential benefit of chemotherapy treatment.
How do genomic tests determine if chemotherapy is necessary?
Genomic tests analyze the activity of a specific set of genes within a tumor to create a “recurrence score.” Instead of looking only at the size of the tumor or whether it has spread to lymph nodes, these tests examine the biological behavior of the cancer cells. According to the Exact Sciences, the developer of Oncotype DX, the test measures the expression of 21 different genes to determine if a patient is likely to benefit from chemotherapy or if hormone therapy alone is sufficient.
The process involves extracting RNA from a paraffin-embedded tumor sample. The lab then measures how often specific genes are “turned on.” High expression of certain genes often correlates with more aggressive tumor growth and a higher likelihood that chemotherapy will effectively shrink the cancer or prevent it from returning. Conversely, a low score suggests the cancer is less aggressive and unlikely to respond significantly to chemotherapy, making the toxic side effects of the treatment unnecessary.
Which breast cancer patients are eligible for these tests?
These tests are not applicable to all breast cancer types. They are specifically designed for patients with early-stage breast cancer that meets three criteria: it must be hormone-receptor-positive (ER+ and/or PR+), HER2-negative, and typically invasive. According to the National Cancer Institute, patients with HER2-positive breast cancer or triple-negative breast cancer generally do not use these specific genomic assays because chemotherapy is already considered a standard, high-benefit requirement for those aggressive subtypes.
Eligibility often depends on the nodal status of the cancer. For patients with node-negative cancer, the decision is often straightforward based on the score. For those with 1 to 3 positive lymph nodes, the New England Journal of Medicine reports that genomic testing is increasingly used to identify a subset of patients who can still avoid chemotherapy despite the presence of lymph node involvement.
What is the difference between Oncotype DX and MammaPrint?
While both tests aim to reduce unnecessary chemotherapy, they use different methodologies and gene sets. Oncotype DX focuses on a 21-gene recurrence score that predicts both the risk of recurrence and the specific benefit of adding chemotherapy to endocrine therapy. MammaPrint, developed by Agendia, focuses on 70 genes to categorize patients as “low risk” or “high risk” for distant metastasis.
| Feature | Oncotype DX | MammaPrint |
|---|---|---|
| Primary Goal | Predicts chemo-benefit and recurrence risk | Predicts risk of distant metastasis |
| Gene Count | 21 Genes | 70 Genes |
| Key Clinical Trial | TAILORx | MINDACT |
| Result Type | Numerical Score (0-100) | Categorical (Low vs. High Risk) |
What evidence supports skipping chemotherapy?
The shift toward chemotherapy avoidance is grounded in large-scale clinical trials. The TAILORx trial, published in the New England Journal of Medicine, followed over 2,500 women and found that for those with a low recurrence score, adding chemotherapy to hormone therapy did not significantly improve disease-free survival. This provided the clinical evidence needed to move away from a “one size fits all” approach to breast cancer treatment.
Similarly, the MINDACT trial supported the use of MammaPrint, showing that patients in the “low risk” category had similar outcomes whether they received chemotherapy or not. These trials demonstrate that for a substantial portion of patients, the risks of chemotherapy—including permanent nerve damage (neuropathy), cardiac toxicity, and immune suppression—outweigh the marginal or non-existent benefits.
What happens if a test shows a high-risk score?
A high-risk score indicates that the tumor is biologically aggressive and more likely to recur without intensive treatment. In these cases, oncologists recommend chemotherapy in addition to hormone therapy. According to the American Society of Clinical Oncology (ASCO), patients with high scores see a statistically significant improvement in survival and a reduction in recurrence rates when chemotherapy is included in their regimen.
The test does not change the treatment for high-risk patients; rather, it provides confirmation that chemotherapy is the correct path. The primary value of the technology lies in its ability to identify the “low-risk” group who can safely omit the drug.
Frequently Asked Questions
- Does a low score mean the cancer is gone? No. A low score means the cancer is less likely to return and less likely to respond to chemotherapy. Patients still require primary treatment, such as surgery and hormone therapy.
- Are these tests covered by insurance? Most major insurance providers and national health systems cover these tests for eligible patients because they reduce the overall cost and morbidity associated with unnecessary chemotherapy.
- Can these tests be done after surgery? Yes, these tests are typically performed on the tumor tissue removed during a lumpectomy or mastectomy.
The integration of genomic profiling marks a transition toward personalized oncology. As research evolves, physicians expect to see more refined assays that can predict response to specific chemotherapy drugs, further reducing toxicity and improving quality of life for cancer survivors.